10/10/2019 8:36:54 AM
Dermira Plans To Present Data From Phase 2b Study Of Lebrikizumab
10/9/2019 8:41:59 AM
Dermira Reports Initiation Of Phase 3 Program Evaluating Lebrikizumab
10/9/2019 8:31:35 AM
Dermira Begins Phase 3 Program Of Lebrikizumab In Patients With Moderate-to-Severe Atopic Dermatitis
6/25/2019 1:32:20 AM
Almirall Exercises Its Option With Dermira To License Rights To Lebrikizumab In Europe For Atopic Dermatitis
3/25/2019 12:04:23 AM
Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign To Highlight QBREXZA Cloth
3/19/2019 8:58:07 PM
Dermira Announces Pricing Of Underwritten Public Offering Of 9.81 Mln Shares At $13.25/shr
3/18/2019 7:08:57 AM
Dermira Announces Positive Topline Results From Phase 2b Study Of Lebrikizumab In Patients With Atopic Dermatitis
2/12/2019 2:16:18 AM
Almirall And Dermira Enter License Agreement For European Rights To Lebrikizumab
12/4/2018 7:34:21 AM
Dermira Reports Closing Of $125 Mln Credit Facility With Athyrium Capital Management
10/1/2018 7:34:35 AM
Dermira’s QBREXZA Cloth Is Now Available In Pharmacies Nationwide For Primary Axillary Hyperhidrosis
6/29/2018 7:03:23 AM
Dermira Receives FDA Approval For Qbrexza Cloth To Treat Primary Axillary Hyperhidrosis
4/19/2018 4:04:41 PM
Dermira Appoints Christopher Horan As Chief Technical Operations Officer